Mikra Cellular Sciences develops CELLF, a novel cellular therapeutic compound intended to boost energy, mental focus and cellular performance by counteracting oxidative stress and promoting mitochondrial creation. CELLF is manufactured in a proprietary oxygen-deprived environment and produced in small batches, and uses a patented transferrin glyco-protein delivery mechanism to target absorption and deliver bioactive compounds directly into cells. The company has a patent pending on CELLF’s formulation and mechanism of action. Mikra is conducting genomic pre-clinical trials with InVivo Biosystems to demonstrate efficacy at a genetic level and plans to continuously improve CELLF as trial results provide new data. A scientific advisory group of physicians and medical researchers will consult on the product. Led by CEO Faraaz Jamal, the company intends to market CELLF while continuing product development.

Total raised

$9M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2022